Withaferin A to prevent GVHD after stem cell transplant
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests a natural compound called Withaferin A (from ashwagandha) to see if it helps prevent graft-versus-host disease (GVHD) after a stem cell transplant. The goal is to reduce the risk of transplant complications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are generally well enough to do daily activities (ECOG score 0 or 1).
- Your liver, kidneys, and heart are working normally.
- If you can become pregnant, you have a negative pregnancy test within 7 days and agree to use birth control.
- You do not have a serious active infection.
- You have no known allergy to Withaferin A.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a plant-based medicine, Withaferin-A, in people whose graft-versus-host disease (GVHD) after a stem cell transplant has not responded to steroid treatment. GVHD is a condition where donated immune cells attack the body; this study aims to see if Withaferin-A can help control it.
This study tests whether an experimental cell therapy called iMSC can help prevent graft-versus-host disease (a common complication after a stem cell transplant). It is given soon after your transplant, within 5 days of enrolling, and aims to reduce the chance of this serious condition.
This study tests a new medicine called axatilimab, given after a stem cell transplant, to help prevent a common complication called graft-versus-host disease (GVHD), where the donor’s cells attack your body. If you are planning a transplant, this may help improve your recovery.
This trial tests a combination of three medicines (sirolimus, ruxolitinib, and mycophenolate mofetil) to prevent graft-versus-host disease (a common complication after a stem cell transplant) in people who cannot take standard anti-rejection drugs. The goal is to find a safer alternative that still protects you from this complication.
This trial tests if a two-step course of a drug called ATG (anti-thymocyte globulin) can help prevent a serious side effect called graft-versus-host disease (GVHD) after a donor stem cell transplant. It is for people with certain blood cancers who are receiving a reduced-intensity transplant.
This trial tests two different medicines (ATG-thymoglobulin and ATLG-grafalon) to prevent graft-versus-host disease (GVHD) after a stem cell transplant. It is for older adults with certain blood cancers who have a matched unrelated donor.
Hear when a new GVHD - Graft-Versus-Host Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.